Trending...
- Tech gains propel Dow Jones past 47,000 as markets reach record highs amid trade tensions
- J French's #1 Album "I Don't Believe in Bad Days" Enters the Grammy Conversation
- Hilton Head Realtor becomes Certified Senior Professional
COLUMBIA, Md.--(BUSINESS WIRE)--Ambu A/S, one of the fastest growing medical device companies and pioneer of sterile, single-use endoscopes, announced today that it is receiving a Global New Product Innovation Award in the advanced visualization market from Frost & Sullivan, a global consulting firm that honors companies it deems to be at the innovation and growth forefront of their respective industries.
Frost & Sullivan selected Ambu due to its work in single-use flexible endoscopy where Ambu is creating an innovation paradigm shift by rapidly bringing new technologies and products in shorter life cycles. An approach which requires advanced modularization capabilities and promotes rapid adoption of new technologies and design improvements.
Disruptive innovation engine
Frost & Sullivan underlines how Ambu has successfully built a unique business model based on a visionary understanding of how endoscopy could be improved by leveraging new technology to better address patient needs.
"Today, Ambu is the most innovative single-use endoscopy player in the market, with a commitment to be at the forefront of technology," said Pavel Zhebrouski, Best Practices Research Analyst at Frost & Sullivan. "Frost & Sullivan feels that Ambu distinctly stands out in the market with its R&D and manufacturing engines, outperforming competitors with its focus on innovation and high-scale, low-cost manufacturing."
More on Marylandian
"Ambu is grateful for this recognition from Frost & Sullivan, whose methodology—focused on disruptive technology and innovative business models—is widely respected," said Ambu A/S CEO Juan Jose Gonzalez. "We have seen the positive impact our single-use endoscopy technology can have by improving productivity and clinical outcomes while ensuring a safe and sterile device for the patient. In the immediate future, you will see a rapid expansion of our innovation pipeline, driven by our world-class innovation organization."
Ambu plans to quadruple its product pipeline and launch more than 20 new flexible endoscopy products in the next three years.
World's largest supplier of single-use flexible endoscopes
Ambu launched the world's first single-use flexible bronchoscope, the Ambu® aScope™, in 2009. In 2020, more than 1 million Ambu single-use endoscopes were used in more than 6,000 hospitals, making Ambu the world's largest supplier of single-use endoscopes.
Within bronchoscopy, 96% of the top 500 hospitals in the United States are using Ambu's sterile, single-use bronchoscopes in the OR and ICU setting. In the last 12 months, Ambu has increased its market share in the U.S. as hospitals continue to transition to single-use bronchoscopy to avoid costly and unnecessary expenses associated with workflow management and patient cross-contamination.
More on Marylandian
About Ambu
Ambu has been bringing the solutions of the future to life since 1937. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring & diagnostics solutions. The manifestations of our efforts have ranged from early innovations like the Ambu® Bag™ resuscitator and the Ambu® BlueSensor™ electrodes to our newest landmark solutions like the Ambu® aScope™ – the world's first single-use flexible endoscope. Moreover, we continuously look to the future with a commitment to deliver innovative quality products that have a positive impact on the work of doctors, nurses and paramedics. Headquartered near Copenhagen in Denmark, Ambu employs approximately 4,000 people in Europe, North America and Asia Pacific. For more information, please visit www.ambu.com or ambuUSA.com.
Frost & Sullivan selected Ambu due to its work in single-use flexible endoscopy where Ambu is creating an innovation paradigm shift by rapidly bringing new technologies and products in shorter life cycles. An approach which requires advanced modularization capabilities and promotes rapid adoption of new technologies and design improvements.
Disruptive innovation engine
Frost & Sullivan underlines how Ambu has successfully built a unique business model based on a visionary understanding of how endoscopy could be improved by leveraging new technology to better address patient needs.
"Today, Ambu is the most innovative single-use endoscopy player in the market, with a commitment to be at the forefront of technology," said Pavel Zhebrouski, Best Practices Research Analyst at Frost & Sullivan. "Frost & Sullivan feels that Ambu distinctly stands out in the market with its R&D and manufacturing engines, outperforming competitors with its focus on innovation and high-scale, low-cost manufacturing."
More on Marylandian
- Full-Circle Learning Sets Sail: WOC STEM Conference and STEM City Travel Launch Cruise-Based AI Leadership Experience with Online and Onboard Training
- Award-Winning Author Zane Carson Carruth Featured in USA Today for Inspiring Mission to Nurture Young Hearts Through Storytelling
- Parkchester Oral & Maxillofacial Surgery Celebrates 450+ 5-Star Reviews
- The AI CEO Partners with D3 Hockey News to Elevate the Voice of Division III Hockey Nationwide
- Statement from the Campaign of Theodis Daniel, Republican for U.S. Congress (TX-18)
"Ambu is grateful for this recognition from Frost & Sullivan, whose methodology—focused on disruptive technology and innovative business models—is widely respected," said Ambu A/S CEO Juan Jose Gonzalez. "We have seen the positive impact our single-use endoscopy technology can have by improving productivity and clinical outcomes while ensuring a safe and sterile device for the patient. In the immediate future, you will see a rapid expansion of our innovation pipeline, driven by our world-class innovation organization."
Ambu plans to quadruple its product pipeline and launch more than 20 new flexible endoscopy products in the next three years.
World's largest supplier of single-use flexible endoscopes
Ambu launched the world's first single-use flexible bronchoscope, the Ambu® aScope™, in 2009. In 2020, more than 1 million Ambu single-use endoscopes were used in more than 6,000 hospitals, making Ambu the world's largest supplier of single-use endoscopes.
Within bronchoscopy, 96% of the top 500 hospitals in the United States are using Ambu's sterile, single-use bronchoscopes in the OR and ICU setting. In the last 12 months, Ambu has increased its market share in the U.S. as hospitals continue to transition to single-use bronchoscopy to avoid costly and unnecessary expenses associated with workflow management and patient cross-contamination.
More on Marylandian
- Maryland: testpost
- Divine Punk Announces Happy Christmas, a Holiday Soundscape by Rebecca Noelle
- $430 Million 2026 Revenue Forecast; 26% Organic Growth; $500,000 Stock Dividend Highlight a Powerful AI & Digital Transformation Story: IQSTEL $IQST
- Wzzph Deploys 5-Million-TPS Trading Engine with Hot-Cold Wallet Architecture Serving 500,000 Active Users Across Latin America
- Preston Dermatology & Skin Surgery Center and Dr. Sheel Desai Solomon Dominate Raleigh's Best Awards from The News & Observer
About Ambu
Ambu has been bringing the solutions of the future to life since 1937. Today, millions of patients and healthcare professionals worldwide depend on the efficiency, safety and performance of our single-use endoscopy, anaesthesia, and patient monitoring & diagnostics solutions. The manifestations of our efforts have ranged from early innovations like the Ambu® Bag™ resuscitator and the Ambu® BlueSensor™ electrodes to our newest landmark solutions like the Ambu® aScope™ – the world's first single-use flexible endoscope. Moreover, we continuously look to the future with a commitment to deliver innovative quality products that have a positive impact on the work of doctors, nurses and paramedics. Headquartered near Copenhagen in Denmark, Ambu employs approximately 4,000 people in Europe, North America and Asia Pacific. For more information, please visit www.ambu.com or ambuUSA.com.
Filed Under: Business
0 Comments
Latest on Marylandian
- Maryland Department of Agriculture Announces Expanded Animal Health Diagnostic Services
- Dr. Johnny Shanks Attends Full Arch Growth Conference 2025
- Offline Asset Protection: NJTRX Implements 98 Percent Cold Storage as Industry Faces 2 Billion USD Losses
- Thousands of Smiles, Millions of Logo Views: RoarFun Brings Emotions Into Premium Retail Spaces with Formula Simulator for Immersive Brand Activation
- Qvarz LLC Expands Global Reach with High-Precision Quartz Cuvettes and Optical Components
- $300 Million Web3 Initiative and ZIGChain Partnership Power $20 Target in Noble Capital Markets Report for SEGG Media (N A S D A Q: SEGG)
- Enrollment Period for Maryland's 2025 Conservation Buffer Initiative Begins November 1st
- Assent Recognizes Manufacturers for Leading Supply Chain Sustainability Programs
- Arc Longevity Sells Out Debut Women's Creatine Gummy
- Frost Locker: New Research Reveals Mild Cold—Not Extreme Cold—Delivers Real Health Benefits of Cold Therapy
- Phinge, Home of Netverse, Through its Extensive Software & Hardware Patent Portfolio, Shows Founder & CEO Robert DeMaio's Vision & Innovation
- OddsTrader Reveals Early Favorites and Best Bets to Win March Madness 2026
- Bookmakers Review Releases 2028 Democratic Nominee Betting Odds: Newsom Leads Early Field
- Heritage at South Brunswick's Townhome Models Coming Soon!
- PatientNow Acquires Recura, the AI Growth Engine Powering Practice Growth
- Boston Industrial Solutions Unveils New and Improved Natron® UV Screen Printing Ink
- Genuine Smiles Unveils New User-Friendly Website
- Nusign Global Launch Event Concludes Successfully, Embarking on a New International Chapter
- Lift Solutions Holdings Announces Exclusive Distributorship for Advanced Camera and Sensor Products from Automate Matrix
- Political Division and Safety Concerns Drive Record Number of Americans to Seek "Golden Visas," La Vida Survey Finds